Weight regain and cardiometabolic effects after withdrawal of semaglutide: The
                    <scp>STEP</scp>
                    1 trial extension

P. H. Wilding, John; L. Batterham, Rachel; Davies, Melanie; F. Van Gaal, Luc; Kandler, Kristian; Konakli, Katerina; Lingvay, Ildiko; M. McGowan, Barbara; Kalayci Oral, Tugce; Rosenstock, Julio; A. Wadden, Thomas; Wharton, Sean; Yokote, Koutaro; F. Kushner, Robert; 1 Study Group, STEP

doi:10.1111/dom.14725

Public

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Shared by NobleBlocks on May 19, 2022 • 12:00 AM UTC

Authors:

John P. H. Wilding

Rachel L. Batterham

Melanie Davies

Abstract

Abstract Aim To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) randomized 1961 adults with a body mass index ≥ 30 kg/m 2 (or ≥ 27 kg/m 2 with ≥ 1 weight‐related co‐morbidity) without...

Discussions